Navigation Links
Anticoagulant Drugs Had Similar Outcomes After Angioplasty
Date:3/30/2008

Study also finds drug-releasing stents appear to work better than uncoated ones

SUNDAY, March 30 (HealthDay News) -- In heart attack patients who had angioplasty, the anticoagulant drugs abciximab and tirofiban produced similar outcomes for certain cardiac measures within 90 minutes after the procedure, says an Italian study.

The researchers also found that patients who received coated stents that released the drug sirolimus had a lower risk of major adverse cardiac events within eight months than patients who received uncoated stents.

The study was to be presented Sunday at the American College of Cardiology annual meeting in Chicago. It was also to be published online Sunday in the Journal of the American Medical Association and will appear in the April 16 print issue.

Treatment with abciximab and implantation of an uncoated stent is a treatment strategy used to reduce the risk of major adverse cardiac events (MACE) in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI - a certain pattern on an electrocardiogram after a heart attack), according to background information in the study.

The researchers noted it hasn't been clear whether using tirofiban instead of abciximab would provide similar benefits. They added that the use of drug-eluting stents instead of uncoated stents in this patient population is discouraged because of safety concerns and conflicting evidence about efficacy.

In this study, Dr. Marco Valgimigli, of the Cardiovascular Institute at the University of Ferrara, and his colleagues compared high-dose tirofiban and sirolimus-releasing stents with abciximab infusion and uncoated stents in 745 patients with STEMI undergoing angioplasty. They found that ST-segment elevation was reduced by at least 50 percent within 90 minutes after angioplasty in 83.6 percent of patients in the abciximab group and in 85.3 percent of those in the tirofiban group.

At eight months, the MACE rate among those treated with tirofiban was 9.9 percent, compared to 12.4 percent in the abciximab group. The MACE rate among patients who received uncoated stents was 14.5 percent, compared with 7.8 percent among those who received the drug-releasing stent. The rate of revascularization (a repeat procedure to unblock a blood vessel) was 3.2 percent among patients who received the drug-coated stent, compared with 10.2 percent among patients who received an uncoated stent.

"In summary, our study provides evidence that in a broad population of largely unselected patients undergoing PCI for STEMI, tirofiban therapy is associated with a noninferior resolution from ST-segment elevation at 90 minutes post-intervention compared with abciximab, and at eight-month follow-up, MACE are approximately halved by sirolimus-eluting stent implantation compared with uncoated stents," the study authors wrote.

More information

The U.S. National Heart, Lung, and Blood Institute has more about angioplasty.



-- Robert Preidt



SOURCES: JAMA/Archives journals, news release, March 30, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Different anticoagulant regimens yield equal results
2. Comparison of anticoagulants for angioplasty show similar outcomes
3. New review suggests caution on drugs to raise good cholesterol
4. Can cancer drugs combine forces?
5. Study provides hope that some transplant patients could live free of antirejection drugs
6. Study provides hope that some transplant patients could live free of anti-rejection drugs
7. RA Drugs Linked to Slight Skin Cancer Risk
8. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
9. Rock N Roll: Sex, Drugs and an Early Exit
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anticoagulant Drugs Had Similar Outcomes After Angioplasty
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 2017 , ... Ultimate Medical Academy today announced the keynote ... March 23-25, 2017 in Tampa, and reminded educators and education leaders to submit ... Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D arm ...
(Date:1/23/2017)... ... ... and plastic balance boards have been around since at least the 1950s and are a ... first and only balance board to use a patent-pending design featuring high-pressure inflation technology and ... as well as skill-level adjustable for all ages and abilities. The board can be ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the premiere organization in North America for the scientific development, healthcare training and ... Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... However, choosing the right method is paramount to success. Selecting an inappropriate measurement ... situations where multiple persons use the same equipment. Rare or expensive substances are ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn in ... expanding at a strong 17.50% CAGR between 2014 and 2022. The ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... Non-invasive ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... SAN DIEGO , 23. Januar 2017  ResMed ... China ) und 3B Medical ( Winter ... sich auf eine Vereinbarung über die Beilegung aller globalen ... ist der Verkauf ihrer bestehenden Produkte im ... eine einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology: